|
1
|
Delaney G, Jacob S, Featherstone C and
Barton M: The role of radiotherapy in cancer treatment: Estimating
optimal utilization from a review of evidence-based clinical
guidelines. Cancer. 104:1129–1137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maier P, Hartmann L, Wenz F and Herskind
C: Cellular pathways in response to ionizing radiation and their
targetability for tumor radiosensitization. Int J Mol Sci.
17:E1022016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Malik A, Sultana M, Qazi A, Qazi MH,
Parveen G, Waquar S, Ashraf AB and Rasool M: Role of natural
radiosensitizers and cancer cell radioresistance: An update. Anal
Cell Pathol (Amst). 2016:61465952016.PubMed/NCBI
|
|
4
|
Wang H, Zhang X, Teng L and Legerski RJ:
DNA damage checkpoint recovery and cancer development. Exp Cell
Res. 334:350–358. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morgan MA and Lawrence TS: Molecular
pathways: Overcoming radiation resistance by targeting DNA damage
response pathways. Clin Cancer Res. 21:2898–2904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Visconti R, Della Monica R and Grieco D:
Cell cycle checkpoint in cancer: A therapeutically targetable
double-edged sword. J Exp Clin Cancer Res. 35:1532016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deckbar D, Jeggo PA and Löbrich M:
Understanding the limitations of radiation-induced cell cycle
checkpoints. Crit Rev Biochem Mol Biol. 46:271–283. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmitt CA: Senescence, apoptosis and
therapy-cutting the lifelines of cancer. Nat Rev Cancer. 3:286–295.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gabrielli B, Brooks K and Pavey S:
Defective cell cycle checkpoints as targets for anti-cancer
therapies. Front Pharmacol. 3:92012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hematulin A, Sagan D, Sawanyawisuth K,
Seubwai W and Wongkham S: Association between cellular
radiosensitivity and G1/G2 checkpoint proficiencies in human
cholangiocarcinoma cell lines. Int J Oncol. 45:1159–1166. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koniaras K, Cuddihy AR, Christopoulos H,
Hogg A and O'Connell MJ: Inhibition of Chk1-dependent G2 DNA damage
checkpoint radiosensitizes p53 mutant human cells. Oncogene.
20:7453–7463. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dillon MT, Good JS and Harrington KJ:
Selective targeting of the G2/M cell cycle checkpoint to improve
the therapeutic index of radiotherapy. Clin Oncol (R Coll Radiol).
26:257–265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JM and Bernstein A: p53 mutations
increase resistance to ionizing radiation. Proc Natl Acad Sci USA.
90:pp. 5742–5746. 1993; View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thakur DS: Topoisomerase II inhibitors in
cancer Treatment. Int J Pharma Sci Nanotechnol. 3:1173–1181.
2011.
|
|
15
|
Schonn I, Hennesen J and Dartsch DC:
Cellular responses to etoposide: Cell death despite cell cycle
arrest and repair of DNA damage. Apoptosis. 15:162–172. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maruyama M, Kobayashi N, Westerman KA,
Sakaguchi M, Allain JE, Totsugawa T, Okitsu T, Fukazawa T, Weber A,
Stolz DB, et al: Establishment of a highly differentiated
immortalized human cholangiocyte cell line with SV40T and hTERT.
Transplantation. 77:446–451. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee YS, Bae SM, Kwak SY, Park DC, Kim YW,
Hur SY, Park EK, Han BD, Lee YJ, Kim CK, et al: Cell cycle
regulatory protein expression profiles by adenovirus p53 infection
in human papilloma virus-associated cervical cancer cells. Cancer
Res Treat. 38:168–177. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hematulin A, Sagan D, Eckardt-Schupp F and
Moertl S: NBS1 is required for IGF-1 induced cellular proliferation
through the Ras/Raf/MEK/ERK cascade. Cell Signal. 20:2276–2285.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amornwichet N, Oike T, Shibata A, Ogiwara
H, Tsuchiya N, Yamauchi M, Saitoh Y, Sekine R, Isono M, Yoshida Y,
et al: Carbon-ion beam irradiation kills X-ray-resistant p53-null
cancer cells by inducing mitotic catastrophe. PLoS One.
9:e1151212014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vakifahmetoglu H, Olsson M and Zhivotovsky
B: Death through a tragedy: Mitotic catastrophe. Cell Death Differ.
15:1153–1162. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fei P and El-Deiry WS: P53 and radiation
responses. Oncogene. 22:5774–5783. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Obchoei S, Weakley SM, Wongkham S,
Wongkham C, Sawanyawisuth K, Yao Q and Chen C: Cyclophilin A
enhances cell proliferation and tumor growth of liver
fluke-associated cholangiocarcinoma. Mol Cancer. 10:1022011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wattanawongdon W, Hahnvajanawong C, Namwat
N, Kanchanawat S, Boonmars T, Jearanaikoon P, Leelayuwat C,
Techasen A and Seubwai W: Establishment and characterization of
gemcitabine-resistant human cholangiocarcinoma cell lines with
multidrug resistance and enhanced invasiveness. Int J Oncol.
47:398–410. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hematulin A, Meethang S, Ingkaninan K and
Sagan D: Derris scandens Benth extract potentiates radioresistance
of Hep-2 laryngeal cancer cells. Asian Pac J Cancer Prev.
13:1289–1295. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morrison R, Schleicher SM, Sun Y, Niermann
KJ, Kim S, Spratt DE, Chung CH and Lu B: Targeting the mechanisms
of resistance to chemotherapy and radiotherapy with the cancer stem
cell hypothesis. J Oncol. 2011:9418762011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mirzayans R, Andrais B, Scott A and Murray
D: New insights into p53 signaling and cancer cell response to DNA
damage: Implications for cancer therapy. J Biomed Biotechnol.
2012:1703252012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Speidel D: The role of DNA damage
responses in p53 biology. Arch Toxicol. 89:501–517. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chung JH and Bunz F: Cdk2 is required for
p53-independent G2/M checkpoint control. PLoS Genet.
6:e10008632010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Passalaris TM, Benanti JA, Gewin L, Kiyono
T and Galloway DA: The G(2) checkpoint is maintained by redundant
pathways. Mol Cell Biol. 19:5872–5881. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K
and Linn S: Molecular mechanisms of mammalian DNA repair and the
DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wasylishen AR and Lozano G: Attenuating
the p53 pathway in human cancers: Many means to the same end. Cold
Spring Harb Perspect Med. 6:a0262112016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim BM and Hong Y, Lee S, Liu P, Lim JH,
Lee YH, Lee TH, Chang KT and Hong Y: Therapeutic implications for
overcoming radiation resistance in cancer therapy. Int J Mol Sci.
16:26880–26913. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rao S, Cunningham D, Hawkins RE, Hill ME,
Smith D, Daniel F, Ross PJ, Oates J and Norman AR: Phase III study
of 5FU, etoposide and leucovorin (FELV) compared to epirubicin,
cisplatin and 5FU (ECF) in previously untreated patients with
advanced biliary cancer. Br J Cancer. 92:1650–1654. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Glimelius B, Hoffman K, Sjödén PO,
Jacobsson G, Sellström H, Enander LK, Linné T and Svensson C:
Chemotherapy improves survival and quality of life in advanced
pancreatic and biliary cancer. Ann Oncol. 7:593–600. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
SIB Bioinformatics Resource Portal
(ExPASy), . Cellosaurus KKU-M214 (CVCL_M264). http://web.expasy.org/cellosaurus/CVCL_M264August
9–2017
|
